JP2014513948A - β２ミクログロブリン欠損細胞 - Google Patents

β２ミクログロブリン欠損細胞 Download PDF

Info

Publication number
JP2014513948A
JP2014513948A JP2014506508A JP2014506508A JP2014513948A JP 2014513948 A JP2014513948 A JP 2014513948A JP 2014506508 A JP2014506508 A JP 2014506508A JP 2014506508 A JP2014506508 A JP 2014506508A JP 2014513948 A JP2014513948 A JP 2014513948A
Authority
JP
Japan
Prior art keywords
cell
cells
hla
protein
hla class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014506508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513948A5 (https=
Inventor
ダブリュ． ラッセル、デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014513948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of JP2014513948A publication Critical patent/JP2014513948A/ja
Publication of JP2014513948A5 publication Critical patent/JP2014513948A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2014506508A 2011-04-20 2012-04-18 β２ミクログロブリン欠損細胞 Pending JP2014513948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477474P 2011-04-20 2011-04-20
US61/477,474 2011-04-20
PCT/US2012/034051 WO2012145384A1 (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018156070A Division JP2018174946A (ja) 2011-04-20 2018-08-23 β２ミクログロブリン欠損細胞

Publications (2)

Publication Number Publication Date
JP2014513948A true JP2014513948A (ja) 2014-06-19
JP2014513948A5 JP2014513948A5 (https=) 2015-05-28

Family

ID=46051930

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014506508A Pending JP2014513948A (ja) 2011-04-20 2012-04-18 β２ミクログロブリン欠損細胞
JP2018156070A Pending JP2018174946A (ja) 2011-04-20 2018-08-23 β２ミクログロブリン欠損細胞
JP2020166783A Active JP7260182B2 (ja) 2011-04-20 2020-10-01 β２ミクログロブリン欠損細胞
JP2023054810A Active JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞
JP2024190215A Pending JP2025010296A (ja) 2011-04-20 2024-10-30 β２ミクログロブリン欠損細胞

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018156070A Pending JP2018174946A (ja) 2011-04-20 2018-08-23 β２ミクログロブリン欠損細胞
JP2020166783A Active JP7260182B2 (ja) 2011-04-20 2020-10-01 β２ミクログロブリン欠損細胞
JP2023054810A Active JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞
JP2024190215A Pending JP2025010296A (ja) 2011-04-20 2024-10-30 β２ミクログロブリン欠損細胞

Country Status (6)

Country Link
US (3) US20140134195A1 (https=)
EP (1) EP2699593B2 (https=)
JP (5) JP2014513948A (https=)
CA (2) CA3205636A1 (https=)
DK (1) DK2699593T4 (https=)
WO (1) WO2012145384A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525344A (ja) * 2014-07-14 2017-09-07 オスペダーレ サン ラファエレ エス．アール．エル ベクター生産
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
JP2020521000A (ja) * 2017-05-23 2020-07-16 ヴァレンティン ブリュッテル， 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2020526224A (ja) * 2017-07-12 2020-08-31 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP2021513839A (ja) * 2018-02-16 2021-06-03 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 改変された多能性幹細胞並びに製造方法及び使用方法
JP2021534813A (ja) * 2018-07-13 2021-12-16 ロタール ゲルメロート 非免疫原性の操作された組織ならびにそれを製造および使用する方法
JP2022526590A (ja) * 2019-04-03 2022-05-25 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP2023509527A (ja) * 2020-01-10 2023-03-08 エルジー・ケム・リミテッド Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
JP2023525579A (ja) * 2020-05-15 2023-06-16 アールエックスセル インコーポレーテッド 低免疫原性の細胞および免疫応答におけるそれらの使用
WO2025070822A1 (ja) * 2023-09-29 2025-04-03 味の素株式会社 Ｈｌａ遺伝子改変細胞

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US20150056225A1 (en) * 2012-04-17 2015-02-26 University Of Washington Through Its Center For Commercialization HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
CA3177929A1 (en) * 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
BR112015030211A2 (pt) * 2013-06-03 2017-08-22 Theravectys Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2016073955A2 (en) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
KR20200075851A (ko) * 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
EP3727467A4 (en) * 2017-12-22 2021-12-01 Centivax, Inc. MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE
EP3754018A4 (en) 2018-02-16 2021-11-24 Kyoto University LOW ANTIGENIC CELL PRODUCTION PROCESS
WO2019231266A1 (ko) * 2018-05-30 2019-12-05 주식회사 강스템바이오텍 Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법
EP3843798A1 (en) 2018-08-31 2021-07-07 Wisconsin Alumni Research Foundation Generating arterial endothelial cell-seeded vascular grafts
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CN113195724A (zh) * 2018-09-26 2021-07-30 新加坡国立大学 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) * 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
EP4048802A4 (en) * 2019-10-22 2023-11-22 The Trustees of Columbia University in the City of New York Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
MX2022011245A (es) 2020-03-11 2023-01-11 Bit Bio Ltd Método de generación de células hepáticas.
WO2021242935A1 (en) * 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
IL300484A (en) 2020-08-19 2023-04-01 Astellas Pharma Inc A human non-naturally occurring modified IgG FC region that specifically binds to a non-naturally occurring modified FC receptor
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022129472A1 (en) 2020-12-18 2022-06-23 Novo Nordisk A/S Safe immuno-stealth cells
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
TW202246494A (zh) * 2021-01-26 2022-12-01 美商艾姆比斯藥品公司 基因改造肝細胞群
TW202302839A (zh) 2021-03-09 2023-01-16 國立研究開發法人理化學研究所 低免疫原性視網膜色素上皮細胞之製造方法
EP4323395A4 (en) * 2021-04-12 2025-04-02 Memorial Sloan Kettering Cancer Center MANIPULATED HLA MOLECULES FOR T CELL AND NK CELL ACTIVATION AND EXPANSION
US20240368541A1 (en) 2021-05-03 2024-11-07 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
WO2022235869A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
EP4407028A4 (en) 2021-09-24 2025-08-06 Cira Found METHOD FOR PRODUCING MODIFIED HUMAN INDUCED PLURIPOTENT STEM CELLS
WO2023069480A1 (en) * 2021-10-20 2023-04-27 Vascugen, Inc. Hypoimmune vasculogenic cells
AU2023246279A1 (en) 2022-04-01 2024-11-14 LogoMix, Inc. Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same
EP4547825A1 (en) 2022-07-01 2025-05-07 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
IL318429A (en) 2022-08-23 2025-03-01 Astellas Inst For Regenerative Medicine Photoreceptor rescue cell (PRC) compositions and methods for treating eye disorders
WO2024044750A2 (en) * 2022-08-26 2024-02-29 Beam Therapeutics Inc. Modified allogeneic cells and methods and compositions for the preparation thereof
EP4610277A1 (en) 2022-10-25 2025-09-03 Daiichi Sankyo Company, Limited Method for avoiding immune rejection using agonist for inhibitory kir
WO2024107551A1 (en) * 2022-11-17 2024-05-23 The Trustees Of Indiana University Novel biomarker and target for treating pulmonary hypertension
WO2024149906A1 (en) 2023-01-13 2024-07-18 Laverock Therapeutics Limited Cell context-specific gene regulation using inhibitory rnas
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2025235955A1 (en) * 2024-05-10 2025-11-13 Bluerock Therapeutics Lp Genetically engineered cells for enhanced immune evasion and methods thereof
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507753A (ja) * 1993-12-30 1997-08-12 セル ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同組換え
JP2004503213A (ja) * 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
JP2009137857A (ja) * 2007-12-04 2009-06-25 Keio Gijuku 癌ワクチン
WO2010052229A1 (en) * 2008-11-07 2010-05-14 Hla-G Technologies Hla-g polypeptides and pharmaceutical uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP0995798A1 (en) 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
FR2856599A1 (fr) * 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
CA2683060C (en) 2007-04-06 2018-01-16 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
KR102366081B1 (ko) 2012-07-31 2022-02-23 에이지엑스 쎄라퓨틱스, 인크. Hla g-변형된 세포 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507753A (ja) * 1993-12-30 1997-08-12 セル ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同組換え
JP2004503213A (ja) * 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
JP2009137857A (ja) * 2007-12-04 2009-06-25 Keio Gijuku 癌ワクチン
WO2010052229A1 (en) * 2008-11-07 2010-05-14 Hla-G Technologies Hla-g polypeptides and pharmaceutical uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELLULAR IMMUNOLOGY, vol. 262, JPN6016044436, 2010, pages 141 - 149, ISSN: 0003443137 *
JOURNAL OF IMMUNOLOGY, vol. 181, JPN6017029485, 2008, pages 6635 - 6643, ISSN: 0003780983 *
MOLECULAR THERAPY, vol. 18, no. 6, JPN6017029488, 2010, pages 1192 - 1199, ISSN: 0003780984 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525344A (ja) * 2014-07-14 2017-09-07 オスペダーレ サン ラファエレ エス．アール．エル ベクター生産
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
JP2023052647A (ja) * 2017-05-23 2023-04-11 ヴァレンティン ブリュッテル， 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2020521000A (ja) * 2017-05-23 2020-07-16 ヴァレンティン ブリュッテル， 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP7793122B2 (ja) 2017-05-23 2026-01-05 ユリウス－マクシミリアンス－ウニヴェルジテート ヴュルツブルク 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2024057078A (ja) * 2017-07-12 2024-04-23 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP7083527B2 (ja) 2017-07-12 2022-06-13 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP2022105691A (ja) * 2017-07-12 2022-07-14 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP7798940B2 (ja) 2017-07-12 2026-01-14 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP2020526224A (ja) * 2017-07-12 2020-08-31 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP7506112B2 (ja) 2017-07-12 2024-06-25 ヴィアサイト，インコーポレイテッド ユニバーサルドナー細胞及び関連方法
JP2021513839A (ja) * 2018-02-16 2021-06-03 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 改変された多能性幹細胞並びに製造方法及び使用方法
JP2021534813A (ja) * 2018-07-13 2021-12-16 ロタール ゲルメロート 非免疫原性の操作された組織ならびにそれを製造および使用する方法
JP7685230B2 (ja) 2018-07-13 2025-05-29 ロタール ゲルメロート 非免疫原性の操作された組織ならびにそれを製造および使用する方法
JP2023116510A (ja) * 2019-04-03 2023-08-22 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP2022526590A (ja) * 2019-04-03 2022-05-25 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP7516617B2 (ja) 2019-04-03 2024-07-16 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP2024153640A (ja) * 2019-04-03 2024-10-29 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
JP2023509527A (ja) * 2020-01-10 2023-03-08 エルジー・ケム・リミテッド Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
JP2023525579A (ja) * 2020-05-15 2023-06-16 アールエックスセル インコーポレーテッド 低免疫原性の細胞および免疫応答におけるそれらの使用
WO2025070822A1 (ja) * 2023-09-29 2025-04-03 味の素株式会社 Ｈｌａ遺伝子改変細胞

Also Published As

Publication number Publication date
JP2018174946A (ja) 2018-11-15
CA2833173A1 (en) 2012-10-26
EP2699593B1 (en) 2017-08-30
DK2699593T4 (da) 2021-02-08
JP7260182B2 (ja) 2023-04-18
EP2699593B2 (en) 2020-11-04
CA3205636A1 (en) 2012-10-26
JP2023073426A (ja) 2023-05-25
CA2833173C (en) 2023-09-05
WO2012145384A1 (en) 2012-10-26
JP2020202880A (ja) 2020-12-24
DK2699593T3 (da) 2017-11-13
US20140134195A1 (en) 2014-05-15
US11813318B2 (en) 2023-11-14
US20190381154A1 (en) 2019-12-19
JP7586528B2 (ja) 2024-11-19
US20240207378A1 (en) 2024-06-27
EP2699593A1 (en) 2014-02-26
JP2025010296A (ja) 2025-01-20

Similar Documents

Publication Publication Date Title
JP7586528B2 (ja) β２ミクログロブリン欠損細胞
JP7531925B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
Zhao et al. Heterelogous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives
JP2020191870A (ja) 治療用細胞のコントロールされた活性化または排除のための方法
JP2021520211A (ja) 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
US9592259B2 (en) APC-mediated tolerance induction for therapy of multiple sclerosis
KR20220010738A (ko) 조절 t 세포에서 제어된 트랜스진 발현
JP2017516752A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
EP1107796A2 (en) Cells expressing immunoregulatory molecules and uses therefor
JP2024522256A (ja) 免疫寛容を誘導するための合成タンパク質
WO2023176986A1 (ja) 免疫寛容誘導用組成物及びその製造方法
CN116406423A (zh) 制备具有所需特异性的效应细胞的方法
WO2024002279A1 (zh) 免疫兼容型人多能干细胞、其制备方法及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20171020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180424